Prostatype Genomics AB (publ), a company listed on Nasdaq First North Growth Market, develops and markets a prognostic gene test to enable assessments and decisions regarding treatment of prostate cancer, has carried out a directed issue of shares raising the company proceeds of SEK 24.7 million (before costs).
The subscription price was determined through an accelerated book building procedure. Sedermera Fondkommission acted sole bookrunner in the transaction.
Lindahl's team consisted of Mattias Prage and Jens Frykstrand.
